Immunogenicity of low doses of hepatitis B vaccine in children: A study in 650 New Zealand children

Milne, A; Dimitrakakis, Mary; Allwood, G K; Lucas, Ron; Cd, Moyes; Pearce, Neil

doi:10.1002/jmv.1890230413

Cited by 8 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In that study of 704 children who were given HBV vaccine at birth, it was shown that 96.7% of 1-to 4-year-old children had detectable anti-HBs, compared to 91% of 5-to 9-year-old children and 81% of 10-to 14-year-old children [12] . In another study, 66% of children aged 5-9 years had antibody titers above 50 IU/ml [13] .…”

Section: Discussionmentioning

confidence: 99%

Assessment of Anti-HBs Antigen in 6- to 9-Year-Old Children Routinely Vaccinated via Vaccination Program in Iran

Hadi¹,

Hadi

2007

Med Princ Pract

View full text Add to dashboard Cite

Objective: To determine persisting antibody levels to hepatitis B virus (HBV) antigen in healthy children, aged 6–9 years, vaccinated at birth. Methods: Blood samples were collected from 374 vaccinated children (178 girls and 196 boys) and 57 unvaccinated children, attending Shiraz Primary School, Shiraz, Iran from September 2002 to April 2003. An HBV surface antibody (anti-HBs) was determined using enzyme-linked immunosorbent assay. Results: The anti-HBs titer was detected in 17% of the 8-year-old children, 7.7% of the 7-year-old children and 46.6% of the 6-year-old children. The decrease was greatest in the 9-year-old children; more than half (54.3%) had a titer of less than 10 IU/ml, indicating a decrease in antibody levels with increasing age/time. Conversely, more than 35% of the 6-year-old children had a titer greater than 150 IU/ml compared with 24, 12 and 7% of children at the age of 7, 8 and 9, respectively, whose antibody titer was less than 150 IU/ml. Conclusion: Antibody titer declined with time. In comparison with other countries, the antibody titer in Iranian children was much lower.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of Anti-HBs Antigen in 6- to 9-Year-Old Children Routinely Vaccinated via Vaccination Program in Iran

Hadi¹,

Hadi

2007

Med Princ Pract

View full text Add to dashboard Cite

show abstract

Low‐dose (2 μg) hepatitis B vaccination in medical students: Comparable immunogenicity for intramuscular and intradermal routes

Heijtink

Knol²,

Schalm

1989

Journal of Medical Virology

View full text Add to dashboard Cite

In a randomized controlled trial, 165 healthy medical students were immunized either by the intramuscular route (IM group) or by the intradermal route (ID group) with low-dose (2 micrograms) plasma hepatitis B vaccine (HB-VAX) at months 0, 1, 2, and 6. At month 7, protective immunity (anti-HBs greater than 10 IU/l) was observed in 90% (95% confidence interval [Cl]: 84-97) of group IM and in 94% (95% Cl: 89-99) of group ID; also geometric mean titres (IM: 533 IU/l; ID:541 IU/l) were very similar at month 7. Sixty-six (IM: 29; ID: 37) of 107 vaccinees with anti-HBs less than 1,000 IU/l at month 7 received a 2 micrograms booster injection at month 12. Long-term immunity (anti-HBs greater than 1,000 IU/l) was finally observed in 58% for group IM and 66% for group ID. For low-dose hepatitis B immunization, which reduces costs to about 16%, the IM route is to be preferred in young healthy individuals in view of an ease of administration, avoidance of long-term local side effects, and the known protective immunity of intramuscularly induced anti-HBs antibodies.

show abstract

Very low dose hepatitis B vaccination in the newborn: Anamnestic response to booster at four years

Moyes

Milne

Waldon

1990

Journal of Medical Virology

View full text Add to dashboard Cite

Seventy-eight children who had received three very low doses (1 or 2 microg) of Merck, Sharp and Dohme (MSD) plasma-derived vaccine (PDV) in early infancy were followed to approximately four years of age. Of the 70 who had responded to the initial course of vaccine with measurable anti-HBs, levels had fallen to below 10 mlU/ml in 38% of subjects given 1 microg doses and in 17% of those who had been given 2 microg doses. None of the children were positive for anti-HBc. Two weeks after 2 microg dose of MSD recombinant DNA (rDNA) vaccine all subjects had more than 10 mlU/ml of anti-HBs, with 90% exceeding 1,000 mlU/ml. A response to hepatitis B vaccine in infancy is followed by an effective immunological memory for several years, even if anti-HBs falls to low levels. The rDNA hepatitis B vaccine (MSD) in 2 microg doses is an effective booster following a primary course of plasma derived vaccine.

show abstract

Immunogenicity of low doses of hepatitis B vaccine in children: A study in 650 New Zealand children

Cited by 8 publications

References 9 publications

Assessment of Anti-HBs Antigen in 6- to 9-Year-Old Children Routinely Vaccinated via Vaccination Program in Iran

Assessment of Anti-HBs Antigen in 6- to 9-Year-Old Children Routinely Vaccinated via Vaccination Program in Iran

Low‐dose (2 μg) hepatitis B vaccination in medical students: Comparable immunogenicity for intramuscular and intradermal routes

Very low dose hepatitis B vaccination in the newborn: Anamnestic response to booster at four years

Contact Info

Product

Resources

About